The genetics of malignant melanoma: lessons from mouse and man
- 1 August 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 3 (8), 559-570
- https://doi.org/10.1038/nrc1145
Abstract
Therapeutic resistance and proclivity for metastasis are hallmarks of malignant melanoma. Genetic, epidemiological and genomic investigations are uncovering the spectrum of stereotypical mutations that are associated with melanoma and how these mutations relate to risk factors such as ultraviolet exposure. The ability to validate the pathogenetic relevance of these mutations in the mouse, coupled with advances in rational drug design, has generated optimism for the development of effective prevention programmes, diagnostic measures and targeted therapeutics in the near future.Keywords
This publication has 107 references indexed in Scilit:
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Limited overlapping roles of P15INK4b and P18INK4c cell cycle inhibitors in proliferation and tumorigenesisThe EMBO Journal, 2000
- Mutation ofPten/Mmac1in mice causes neoplasia in multiple organ systemsProceedings of the National Academy of Sciences of the United States of America, 1999
- High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in miceCurrent Biology, 1998
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- Germline mutations in the PTEN/MMAC1 gene in patients with Cowden diseaseHuman Molecular Genetics, 1997
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993